The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...
FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
The company plans to submit an Investigational New Drug application or foreign equivalent for APG279. The company says cash, cash equivalents, and marketable securities were $731.1 million as of ...
Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technologyâ„¢ platform to rapidly optimize and derisk drug discovery and development, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results